Table 1.

Summary of clinical trials included in meta-analysis.

Trial/year	Sample size	Mean age (men/women)	Patient entry criteria	Experiment group	Control group	Treatment duration	Outcome measures
Zhou, 2010	Exp:63	61–87	NP	Ginkgo biloba tablet 480 mg/d	Atorvastatin 20 mg/d	26 weeks	TG, TC, LDL-C, HDL-C
	Con:62	(66/59)	LDL-C ≥ 3.4 mmol/L, TG ≥ 1.7 mmol/L	LDL-C ≥ 3.4 mmol/L, TG ≥ 1.7 mmol/L
Guo and Ju, 2011	Exp:40	46–79	TC ≥ 5.72 mmol,	Ginkgo biloba pill 480 mg/d +	Atorvastatin 20 mg/d	24 weeks	TC, LDL-C, HDL-C, AE
	Con:39	(44/36)	LDL-C ≥ 3.64 mmol/L, and/or HDL-C ≤ 1.04 mmol/L	atorvastatin 20 mg/d
Zhong and Bao, 2011	Exp:30	39–78	TC ≥ 5.2 mmol,	Ginkgo biloba tablet 240 mg/d	Atorvastatin 10 mg/d	6 weeks	TG, TC, LDL-C, HDL-C
	Con:29	(29/30)	LDL-C ≥ 3.64 mmol/L, TG ≥ 1.7 mmol/L	+ atorvastatin 10 mg/d
Lin et al., 2011	Exp:32	28–76	TC ≥ 5.2 mmol,	Ginkgo biloba tablet 240 mg/d	Atorvastatin 10 mg/d	6 weeks	TG, TC, LDL-C, HDL-C, AE
	Con:32	(35/29)	LDL-C ≥ 3.4 mmol/L, TG ≥ 1.7 mmol/L	+ atorvastatin 10 mg/d
Jin et al., 2012	Exp:33	36–71	TC ≥ 5.2 mmol,	Ginkgo biloba tablet 240 mg/d	Rosuvastatin 10 mg/d	4 weeks	TG, TC, LDL-C, HDL-C, AE
	Con:32	(36/29)	LDL-C ≥ 3.64 mmol/L, TG ≥ 1.7 mmol/L	+ rosuvastatin 10 mg/d
Ren, 2012	Exp:41	Exp:54.8 ± 3.2/(NP)	TC ≥ 5.2 mmol,	Ginkgo biloba tablet 576 mg/d	Simvastatin 20 mg/d	8 weeks	TG, TC, LDL-C, HDL-C
	Con:41	Con:59.1 ± 4.6/(NP)	LDL-C ≥ 3.4 mmol/L, TG ≥ 1.7 mmol/L	+ simvastatin 20 mg/d
Zhu, 2012	Exp:65	42–78	TC ≥ 5.752 mmol,	Ginkgo biloba capsule	Simvastatin 10 mg/d	6 weeks	TG, TC, LDL-C, HDL-C
	Con:65	(62/58)	LDL-C ≥ 3.64 mmol/L, and/or HDL-C ≤ 1.04 mmol/L, TG ≥ 1.7 mmol/L	120 mg/d + simvastatin 20 mg/d
Xu, 2013	Exp:30	47–80	TC ≥ 5.2 mmol,	Ginkgo biloba tablet	Simvastatin 20 mg/d	8 weeks	TG, TC, LDL-C, HDL-C
	Con:30	(37/23)	LDL-C ≥ 3.4 mmol/L, TG ≥ 1.7 mmol/L	240 mg/d + simvastatin 20 mg/d

Exp, experiment; Con, control; TGs, triglycerides; TC, total cholesterol; LDL-C, low density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol.